RANICLOR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RANICLOR (RANICLOR).
Ranitidine is a histamine H2-receptor antagonist that competitively inhibits the action of histamine on parietal cells, thereby reducing gastric acid secretion.
| Metabolism | Primarily hepatic metabolism via N-demethylation, N-oxidation, and S-oxidation; minor role of renal excretion. Not highly dependent on CYP450 enzymes; predominantly metabolized by flavin-containing monooxygenases (FMOs). |
| Excretion | Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug. |
| Half-life | Terminal elimination half-life: 8-12 hours (mean 10 hours) in healthy adults; prolonged in renal impairment (up to 20 hours) and elderly. |
| Protein binding | Plasma protein binding: 80-85%, primarily to albumin and α1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution: 3-5 L/kg, indicating extensive tissue distribution; high binding to cardiac and skeletal muscle. |
| Bioavailability | Oral bioavailability: 60-70% due to first-pass hepatic metabolism; intramuscular: 85-95%. |
| Onset of Action | Oral: 30-60 minutes; intravenous: within 5 minutes. |
| Duration of Action | Oral: 8-12 hours; intravenous: 6-8 hours; clinical effects correlate with plasma concentration above therapeutic threshold. |
12.5 mg orally twice daily, increased to 25 mg twice daily after 2 weeks if tolerated; maximum 50 mg twice daily.
| Dosage form | TABLET, CHEWABLE |
| Renal impairment | CrCl 15-29 mL/min: 12.5 mg orally once daily; CrCl <15 mL/min or on hemodialysis: not recommended. |
| Liver impairment | Child-Pugh A: 12.5 mg orally once daily; Child-Pugh B or C: contraindicated. |
| Pediatric use | Not recommended for use in patients <18 years of age due to lack of safety and efficacy data. |
| Geriatric use | No specific adjustment; use with caution due to age-related renal impairment and increased risk of adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RANICLOR (RANICLOR).
| Breastfeeding | Cefaclor is excreted into human milk in low concentrations (M/P ratio approximately 0.15-0.5). It is considered compatible with breastfeeding because of low oral bioavailability in infants. However, potential for alteration of infant gut flora and sensitization. Monitor infant for diarrhea, rash, or candidiasis. |
| Teratogenic Risk | Raniclor (cefaclor) is a second-generation cephalosporin. No adequate and well-controlled studies in pregnant women. Animal studies have not shown teratogenic effects. First trimester: risk not fully characterized; avoid unless clearly needed. Second and third trimesters: considered low risk; use if clinically indicated. Fetal adverse effects are unlikely based on limited human data. |
■ FDA Black Box Warning
No FDA black box warning is currently documented for ranitidine.
| Serious Effects |
Known hypersensitivity to ranitidine or other H2 antagonists; acute porphyria; use with caution in patients with hepatic or renal impairment; not recommended for children <1 month.
| Precautions | Use with caution in patients with hepatic or renal impairment; may cause confusion, delirium, or hallucinations in elderly or critically ill patients; possible risk of gastric malignancy in long-term use; potential for acute porphyria; may elevate liver enzymes; avoid abrupt discontinuation in severe cases; pregnancy category B. |
Loading safety data…
| Fetal Monitoring | Monitor maternal renal function during prolonged therapy. No specific fetal monitoring required; routine prenatal care. Observe for hypersensitivity reactions. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Human data lacking. |